结直肠癌的免疫治疗：是针对少数人还是所有人？
Immunotherapy in colorectal cancer: for the select few or all?
作者信息
Arora Sukeshi Patel, Mahalingam Devalingam
机构信息
University of Texas Health Science Center San Antonio, 7979 Wurzbach Rd, MC8026, San Antonio, TX 78229, USA.
出版信息
J Gastrointest Oncol. 2018 Feb;9(1):170-179. doi: 10.21037/jgo.2017.06.10.
Abstract
Over the past few years, the role of immunotherapy in colorectal cancer (CRC) has expanded, specifically in subsets of CRC with microsatellite instability (MSI) for which newer agents, such as programmed death-1 (PD-1) inhibitors, are efficacious. While other immunotherapeutic agents are more immature in development, they have the potential to enhance the efficacy of PD-1 inhibitors and play a role in the treatment algorithm for all subsets of CRC patients. In this review, we will discuss immunotherapeutic agents in development in patients with CRC. We will review the later phase studies that elucidate the role of immunotherapy in CRC and provide hope for changing the treatment paradigm for CRC in the future.
摘要
在过去几年中，免疫疗法在结直肠癌（CRC）中的作用不断扩大，特别是在微卫星不稳定（MSI）的CRC亚组中，针对这类患者，新型药物如程序性死亡-1（PD-1）抑制剂具有疗效。虽然其他免疫治疗药物尚处于更不成熟的研发阶段，但它们有可能提高PD-1抑制剂的疗效，并在所有CRC患者亚组的治疗方案中发挥作用。在本综述中，我们将讨论正在研发中的用于CRC患者的免疫治疗药物。我们将回顾阐明免疫疗法在CRC中的作用的后期研究，并为未来改变CRC的治疗模式带来希望。
相似文献
1
Immunotherapy in colorectal cancer: for the select few or all?结直肠癌的免疫治疗：是针对少数人还是所有人？
J Gastrointest Oncol. 2018 Feb;9(1):170-179. doi: 10.21037/jgo.2017.06.10.
2
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.程序性死亡配体-1检测及免疫疗法在微卫星不稳定型结直肠癌中是否有作用？第二部分——程序性死亡配体-1检测的挑战及其在微卫星高度不稳定型结直肠癌中的作用
Arch Pathol Lab Med. 2018 Jan;142(1):26-34. doi: 10.5858/arpa.2017-0041-RA. Epub 2017 Nov 9.
3
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.程序性死亡配体-1检测及免疫疗法在微卫星不稳定的结直肠癌中是否有作用？第一部分——结直肠癌：微卫星不稳定、检测及临床意义
Arch Pathol Lab Med. 2018 Jan;142(1):17-25. doi: 10.5858/arpa.2017-0040-RA. Epub 2017 Nov 16.
4
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.免疫疗法在结直肠癌中的潜在价值：程序性死亡-1抑制剂治疗的证据综述
Clin Colorectal Cancer. 2016 Dec;15(4):285-291. doi: 10.1016/j.clcc.2016.07.007. Epub 2016 Jul 22.
5
A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.一部分微卫星稳定/微卫星低度不稳定的结直肠癌患者表现出CD8(+)肿瘤浸润淋巴细胞增加以及干扰素-γ上调。
Oncol Lett. 2019 Dec;18(6):5977-5985. doi: 10.3892/ol.2019.10953. Epub 2019 Oct 2.
6
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.结直肠癌免疫治疗的生物标志物：错配修复缺陷及其他。
J Gastrointest Oncol. 2016 Oct;7(5):713-720. doi: 10.21037/jgo.2016.07.03.
7
Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.错配修复缺陷型结直肠癌的免疫治疗进展及未来治疗挑战
Cancer J. 2016 May-Jun;22(3):190-5. doi: 10.1097/PPO.0000000000000196.
8
[Immunotherapy of Colorectal and Anal Carcinoma].[结直肠癌和肛管癌的免疫治疗]
Klin Onkol. 2017 Winter;30(Supplementum3):62-65. doi: 10.14735/amko20173S62.
9
Immune checkpoints and immunotherapy for colorectal cancer.免疫检查点和免疫疗法治疗结直肠癌。
Gastroenterol Rep (Oxf). 2015 Nov;3(4):289-97. doi: 10.1093/gastro/gov053. Epub 2015 Oct 27.
10
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.PD-1/PD-L1 阻断作为结直肠癌的一种新治疗方法。
Biomed Pharmacother. 2019 Feb;110:312-318. doi: 10.1016/j.biopha.2018.11.105. Epub 2018 Dec 3.
引用本文的文献
1
Novel Protein Adjuvant Activating Innate IFN-γ and IL-18 Expression and Inducing Rejection of Implanted Colorectal Cancer Following Immunotherapy Using This Adjuvant in Mice.新型蛋白质佐剂激活先天性IFN-γ和IL-18表达，并在小鼠中使用该佐剂进行免疫治疗后诱导植入的结直肠癌排斥反应。
Med Res Arch. 2025 Jun;13(6). doi: 10.18103/mra.v13i6.6615. Epub 2025 Jun 30.
2
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.呋喹替尼对比安慰剂治疗难治性转移性结直肠癌患者：FRESCO-2安全性分析
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae360.
3
Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis.结肠腺癌中APC和TP53相关肿瘤微环境的免疫景观：一项生物信息学分析。
Eur J Microbiol Immunol (Bp). 2024 Mar 12;14(2):154-165. doi: 10.1556/1886.2024.00015. Print 2024 May 14.
4
Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence.采用包膜型自我扩增mRNA CARG-2020进行癌症免疫治疗，该疗法可调节白细胞介素-12、白细胞介素-17和程序性死亡受体配体-1通路以预防肿瘤复发。
Acta Pharm Sin B. 2024 Jan;14(1):335-349. doi: 10.1016/j.apsb.2023.08.034. Epub 2023 Sep 9.
5
A Novel Protozoa Parasite-Derived Protein Adjuvant Is Effective in Immunization with Cancer Cells to Activate the Cancer-Specific Protective Immunity and Inhibit the Cancer Growth in a Murine Model of Colorectal Cancer.一种新型原生动物寄生虫衍生蛋白佐剂与癌细胞免疫接种有效，可激活针对癌症的特异性保护免疫，并抑制结直肠癌小鼠模型中的癌症生长。
Cells. 2024 Jan 6;13(2):111. doi: 10.3390/cells13020111.
6
Generation and characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen.生成并鉴定一种针对癌胚抗原的新型高亲和力人源抗体。
MAbs. 2023 Jan-Dec;15(1):2217964. doi: 10.1080/19420862.2023.2217964.
7
Natural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer.天然化合物靶向自噬通路治疗结直肠癌。
Int J Mol Sci. 2023 Apr 15;24(8):7310. doi: 10.3390/ijms24087310.
8
Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses.靶向 Cbl-b-Notch1 轴作为一种新的免疫治疗策略，以增强 CD8+T 细胞反应。
Front Immunol. 2022 Aug 26;13:987298. doi: 10.3389/fimmu.2022.987298. eCollection 2022.
9
Associations of different immune checkpoints-expressing CD4 Treg/ T cell subsets with disease-free survival in colorectal cancer patients.不同免疫检查点表达的 CD4+Treg/T 细胞亚群与结直肠癌患者无病生存的关系。
BMC Cancer. 2022 Jun 2;22(1):601. doi: 10.1186/s12885-022-09710-1.
10
The role of microbiota in colorectal cancer.肠道微生物群在结直肠癌中的作用。
Folia Microbiol (Praha). 2022 Oct;67(5):683-691. doi: 10.1007/s12223-022-00978-1. Epub 2022 May 10.
本文引用的文献
1
Phase II/III Study of Radiofrequency Ablation Combined with Cytokine-Induced Killer Cells Treating Colorectal Liver Metastases.射频消融联合细胞因子诱导的杀伤细胞治疗结直肠癌肝转移的II/III期研究
Cell Physiol Biochem. 2016;40(1-2):137-145. doi: 10.1159/000452531. Epub 2016 Nov 18.
2
Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms.微生物群驱动的结直肠癌致癌作用：模型与机制
Free Radic Biol Med. 2017 Apr;105:3-15. doi: 10.1016/j.freeradbiomed.2016.10.504. Epub 2016 Oct 31.
3
Metabolite and Microbiome Interplay in Cancer Immunotherapy.癌症免疫治疗中的代谢物与微生物组相互作用
Cancer Res. 2016 Nov 1;76(21):6146-6152. doi: 10.1158/0008-5472.CAN-16-0309. Epub 2016 Oct 11.
4
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
5
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.阿替利珠单抗用于接受铂类化疗后病情进展的局部晚期和转移性尿路上皮癌患者：一项单臂、多中心、2期试验。
Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.
6
Microsatellite Instability as a Biomarker for PD-1 Blockade.微卫星不稳定性作为 PD-1 阻断的生物标志物。
Clin Cancer Res. 2016 Feb 15;22(4):813-20. doi: 10.1158/1078-0432.CCR-15-1678.
7
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer.结肠癌中肿瘤浸润效应性TIM-3⁺CD8⁺ T细胞的凋亡
Sci Rep. 2015 Oct 23;5:15659. doi: 10.1038/srep15659.
8
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
9
Peptide Vaccine Therapy in Colorectal Cancer.肽疫苗疗法在结直肠癌中的应用
Vaccines (Basel). 2012 Aug 24;1(1):1-16. doi: 10.3390/vaccines1010001.
10
Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.Tim-3的上调与结肠癌患者的不良预后相关。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8018-27. eCollection 2015.
Zotero 插件